Prognostic implication of choroidal thickness in ranibizumab‐treated eyes with neovascular age‐related macular degeneration (nvAMD)

Abstract

Purpose To evaluate prognostic factors in newly diagnosed nvAMD. Methods Forty eyes of 37 patients with nvAMD received 0.5mg of intravitreal ranibizumab (IVR) monthly. One month after the third IVR, responders were defined as patients having improved visual acuity without retinal fluid. Results 22 eyes (55%) were responders. Multivariate logistic regression identified thicker subfoveal choroidal thickness (SFCT) (p=0.049) and smaller choroidal neovascularization (p=0.043) as predictive factor for responder. SFCT were significantly thicker in responders (257 vs. 167 μm) even after adjusting for age and spherical equivalent. (p=0.024) Conclusion Thinner choroidal thickness is negative prognostic factor for response to IVR in nvAMD.